Compared to the PARP1 rs8679 AA genotype, the protective effect of AG/GG genotypes were more predominant in the patients with BMI < 24 (adjusted OR=0.27, 95% CI=0.08-0.96, P=0.043), menarche age ≤ 14 (adjusted OR=0.09, 95% CI=0.01-0.65, P=0.017) and serous carcinoma (adjusted OR=0.36, 95% CI=0.14-0.98, P=0.045). Here, PARP1 is linked to serous adenocarcinoma.